Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Intranasal Therapeutics, Inc.
U.S. patent approval granted for multiple drug dose delivery device
November 4th, 2005
Intranasal Therapeutics, Inc., (ITI) announced that the U.S. Patent Office has approved a patent for a multiple unit dose delivery device to which ITI holds exclusive worldwide licensing rights. The programmable delivery system, the product of a research relationship between ITI and the University of Kentucky, is suited for the nasal delivery of narcotics and controlled substances and for ensuring patient compliance. The device can deliver up to 12 individually packaged doses of medication, and it features an electronic lockout system to ensure that a drug is administered no more frequently than the prescription permits. In addition, since doses are...
Source: Biotech Law Weekly (2005-11-04)
|
